RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.
- Dr. Leonid Melamed Founding Partner
- Dr. Vladimir Gurdus Founding Partner, CEO
- Victor Stankevich Founding Partner
- Dr. Evgeny Zaytsev Managing Partner
- Maxim Gorbachev Managing Partner
- Dr. Mikhail Getman Partner, Medical/Scientific
- Evgeny Arkhipov Legal Affairs Director
- Emil Gafarov Principal
- Maria Makarova CFO
17 October 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.
17 October 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia ("MLL") protein. These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene ("MLL-r"). Syndax expects to initiate clinical studies in 2019.